DSTP3086S: Phase I data

An open-label, dose-escalation, U.S. Phase I trial in 28 patients with CRPC showed that the recommended Phase II dose of IV DSTP3086S was 2.8

Read the full 241 word article

How to gain access

Continue reading with a
two-week free trial.